Catalog No.: PC-49672Not For Human Use, Lab Use Only.
MS3227 is a proteolysis-targeting chimera (PROTAC) that targets MDM2 by recruiting the E3 ligase VHL, resulting in proteasome-dependent degradation of MDM2.
MS3227 is a proteolysis-targeting chimera (PROTAC) that targets MDM2 by recruiting the E3 ligase VHL, resulting in proteasome-dependent degradation of MDM2.
In WT TP53 leukemia cell lines, MS3227 led to activation of p53 targets p21, PUMA, and MDM2 and resulted in cell-cycle arrest, apoptosis, and decreased viability.
MS3227 also shows potent effect in primary patient specimens with selectivity towards leukemic blasts.
MS3227 enhanced the activity of other anti-leukemic agents including azacytidine, cytarabine, and venetoclax.
MS3227 treatment was shown to downregulate MCL-1, a known mediator of resistance to venetoclax.
